Key facts
- Circle Pharma’s last known valuation is $269.0M (Jan 2025).
- It has raised $212.1M across 4 recorded rounds; the latest was Later Stage VC ($92.4M) in Jun 2024.
- Notable investors include Hemisphere Ventures, CSC UpShot Ventures, Mission BioCapital, Pfizer Ventures, Euclidean Capital — 23 tracked in total.
- Circle Pharma has filed 7 Form Ds with the SEC since 2016, most recently Jan 2025 ($92.4M sold to 14 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 23 names
- ·Watchlist + deal alerts for Circle Pharma
Funding rounds
4 roundsAbout Circle Pharma
Developer of a new generation of macrocycle therapies designed for cell-permeable delivery and can be delivered by multiple routes, including oral administration. The company's platform combines structure-based rational drug design and advanced synthetic chemistry to develop first-in-class macrocycle therapeutics for challenging targets to address unmet clinical needs, enabling doctors to focus on internal development efforts on intracellular protein-protein interactions that are key drivers in cancer.
- Sector
- Healthcare
- HQ
- South San Francisco, CA, United States
- Founded
- 2012
- Employees
- 56
- Website
- circlepharma.com/
- Ownership
- Privately Held (backing)
Circle Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Circle Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Circle Pharma in its N-PORT filings yet. We sweep new filings monthly.